Remicade
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
Top Ten most popular articles on Pharmafile.com this week
June 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma
Summer seems to be in full swing as we reach the end of June, so it’s time to look back …
Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis
June 27, 2018Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis
Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …
Novartis’ Sandoz scores EU approval for Remicade biosimilar
May 24, 2018Sales and Marketing EU, Europe, Novartis, Remicade, Sandoz, Zessly, pharma
The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …
Top Ten most popular articles on Pharmafile.com this week
January 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate
As we come to the end of January, it’s Friday again – time for another rundown of the top ten …
US court upholds ruling that J&J’s Remicade patent is invalid
January 24, 2018Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma
The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says
October 30, 2017Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma
Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …
MSD under CMA investigation over unfair Remicade pricing
May 24, 2017Research and Development, Sales and Marketing Competition and Marketing Authority, MSD, Remicade
MSD is facing legal trouble after the Competition and Marketing Authority (CMA) alleged that the pharmaceutical firm had engaged in …
J&J launches lawsuit to block release of Remicade biosimilar
May 19, 2017Medical Communications, Sales and Marketing J&J, JJ, Remicade, Samsung Bioepis
Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but …
Pfizer’s Remicade biosimilar displays similar efficacy
February 22, 2017Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …
Pfizer sets release date for rival to J&J’s blockbuster drug
October 18, 2016Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …
J&J loses Remicade patent fight, pledges to continue fight against biosimilars
August 18, 2016Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent
Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
Samsung Bioepis’ Remicade biosimilar set for CHMP verdict
March 31, 2016Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab
Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
